Pfizer's $14B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
admin 5th June 2017 Uncategorised 0The annual ASCO meeting often throws new light on old drugs—and old dealmaking. This year, it’s last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—that doesn’t look so impressive anymore, thanks to data rolled out over the weekend.
More: Pfizer's B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
Source: fierce